Search

Your search keyword '"Evans, John N."' showing total 38 results
Start Over Author "Evans, John N." Language english
38 results on '"Evans, John N."'

1. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Author

Gornik, Heather L., Aronow, Herbert D., Goodney, Philip P., Arya, Shipra, Brewster, Luke Packard, Byrd, Lori, Chandra, Venita, Drachman, Douglas E., Eaves, Jennifer M., Ehrman, Jonathan K., Evans, John N., Getchius, Thomas S.D., Gutiérrez, J. Antonio, Hawkins, Beau M., Hess, Connie N., Ho, Karen J., Jones, W. Schuyler, Kim, Esther S.H., Kinlay, Scott, Kirksey, Lee, Kohlman-Trigoboff, Debra, Long, Chandler A., Pollak, Amy West, Sabri, Saher S., Sadwin, Lawrence B., Secemsky, Eric A., Serhal, Maya, Shishehbor, Mehdi H., Treat-Jacobson, Diane, and Wilkins, Luke R.

Published
2024
Full Text
View/download PDF

8. Updates in PAD Diagnosis and Treatment.

Author

Nakajima, Yukari, Eno, Yuka, Hirata, Mariko, Kobori, Sawako, Sugiura, Ayano, Takeuchi, Maiko, Taniguchi, Miho, Tanisaki, Megumi, Hayashi, Asuka, Hikishima, Keiko, Matsuo, Naoki, Wada, Natsumi, Mukai, Kanae, Murakado, Naoko, Okuwa, Mayumi, Nakatani, Toshio, and Evans, John N.

Published
2023

13. DESPITE HIGHER TAX RATES, S CORPORATIONS RETAIN ADVANTAGES OVER C CORPORATIONS.

Author

EVANS, JOHN N. and CASTILLA, MARIA L.

Abstract

The article explains why operating as an S corporation, a pass-through entity whose shareholders are subject to personal income tax based on the income of the corporation, still remains the wiser choice, while individual rates have gone up. It discusses the Medicare tax exclusion for material participation, the double taxation disadvantage, and the risk of double taxation of corporate income involving the sale of a business.

Published
2013

17. Head and neck manifestation of histiocytosis-x.

Author

H. Smith, Richard J. and G. Evans, John N.

Abstract

Histiocytosis-X is an uncommon disease, but is relevant to the otolaryngologist because patients with this malady present with, or ultimately develop, head and neck manifestations. Sixty-two patients with histologically confirmed histiocytosis-X have been examined at the Hospital for Sick Children in London since 1958. Most patients were under 2 years of age on initial examination and had either osseous or dermatologic disease involvement. Less commonly, otic or oral lesions were found. Histiocytosis-X is a systemic disease and must be treated accordingly. Isolated lesions may mimic common disease processes, therefore it is imperative that if a seemingly simple problem does not resolve with routine therapy, further patient evaluation be undertaken, If diagnosed, histiocytosis-X can generally be controlled with Steroid therapy, or in more recalcitrant cases, by the addition of chemotherapy. [ABSTRACT FROM AUTHOR]

Published
1984
Full Text
View/download PDF

38. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Author

Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, Chandra V, Drachman DE, Eaves JM, Ehrman JK, Evans JN, Getchius TSD, Gutiérrez JA, Hawkins BM, Hess CN, Ho KJ, Jones WS, Kim ESH, Kinlay S, Kirksey L, Kohlman-Trigoboff D, Long CA, Pollak AW, Sabri SS, Sadwin LB, Secemsky EA, Serhal M, Shishehbor MH, Treat-Jacobson D, and Wilkins LR

Subjects
Humans, United States, Cardiology standards, Societies, Medical standards, Peripheral Arterial Disease therapy, Peripheral Arterial Disease diagnosis, Lower Extremity blood supply, American Heart Association
Abstract

Aim: The "2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease" provides recommendations to guide clinicians in the treatment of patients with lower extremity peripheral artery disease across its multiple clinical presentation subsets (ie, asymptomatic, chronic symptomatic, chronic limb-threatening ischemia, and acute limb ischemia)., Methods: A comprehensive literature search was conducted from October 2020 to June 2022, encompassing studies, reviews, and other evidence conducted on human subjects that was published in English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and other selected databases relevant to this guideline. Additional relevant studies, published through May 2023 during the peer review process, were also considered by the writing committee and added to the evidence tables where appropriate., Structure: Recommendations from the "2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing comprehensive care for patients with peripheral artery disease have been developed., (Copyright © 2024 American College of Cardiology Foundation and the American Heart Association, Inc. Published by Elsevier. Published by Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results